Read the Blog
Choosing the right CRO as a partner for your drug development programs is a vitally important step to achieving critical decision making early on for important milestones, and ultimately getting your molecule from discovery to market efficiently.
Bring your talents and forward-thinking approach to Altasciences and help us develop medicines for those who need them, faster. We have a number of opportunities for you to explore.
Related Press Release
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
As part of our full service offering or as standalone solutions
From formulation development, phase I through commercial manufacturing, and ICH stability testing
Read the Blog
Choosing the right CRO as a partner for your drug development programs is a vitally important step to achieving critical decision making early on for important milestones, and ultimately getting your molecule from discovery to market efficiently.
Working as a flexible, attentive extension of your team, we offer all you need to move your molecule forward.
